search
Back to results

Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease (GumD)

Primary Purpose

Periodontal Disease, Vitamin D Deficiency

Status
Unknown status
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Cholecalciferol
Placebo
Sponsored by
Augusta University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Periodontal Disease

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. You are African American
  2. You have generalized chronic moderate to severe gum disease (periodontitis)
  3. Your age is between 18-60 years.
  4. You are not taking any vitamin, mineral or herbal supplements
  5. If you are a female, you are not pregnant

Exclusion Criteria:

  • Not meeting any of the above

Sites / Locations

  • Georgia Prevention InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

cholecalciferol

Placebo

Arm Description

Subjects will take 4000 IU per day for 30 days

Subjects will take placebo everyday for 30 days

Outcomes

Primary Outcome Measures

Change in Periodontal Disease Activity
Periodontal disease activity will be measured using standard periodontal disease measures of pocket depth, blood on probing, periodontal inflamed surface area, plaque scores, bone loss, and clinical attachment loss
Change in Cardiometabolic Risk Factors
Cardiometabolic risk factors will be measured by pulse wave velocity, central and peripheral blood pressure and glycated hemoglobin (A1C)

Secondary Outcome Measures

Change in Blood Myeloid Dendritic Cells
Relative gene expression (transcripts) in blood myeloid dendritic cells (mDCs) by polymerase chain reaction (PCR) array, validated by protein, of markers of DC homeostasis and atherogenesis.

Full Information

First Posted
December 11, 2014
Last Updated
January 8, 2015
Sponsor
Augusta University
search

1. Study Identification

Unique Protocol Identification Number
NCT02337257
Brief Title
Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease
Acronym
GumD
Official Title
Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans
Study Type
Interventional

2. Study Status

Record Verification Date
January 2015
Overall Recruitment Status
Unknown status
Study Start Date
April 2014 (undefined)
Primary Completion Date
September 2015 (Anticipated)
Study Completion Date
December 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Augusta University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Poor vitamin D status is very common in African Americans. Periodontitis (gum disease) are shown to be related to theincreased risk of cardiometabolic diseases. Vitamin D is freely available and cheap supplement that has shown beneficialeffect in the immune system regulation and maintenance of the cardiovascular health. In this study The investigators hypothesize thatvitamin D supplementation for 16 weeks in African Americans with periodontitis will result in clinical improvement in theirgum health as well as their cardiometabolic risk profile
Detailed Description
This is a double-blind placebo-controlled randomized clinical trial of vitamin D supplementation. The eligible subjects will be assigned to a specific group by random assignment in one of the following two groups: Group 1 who will receive placebo. Group 2 who will receive 4,000 IU vitamin D. Both groups will receive either the placebo pills or vitamin D supplementation everyday for 16 weeks. At visit 1: a fasting morning urine sample will be collected. Height, weight, hip and waist circumferences will be measured. Automatic and manual blood pressures will be measured in sitting position. Approximately 80 ml of venous blood will be collected. Arterial stiffness will be assessed non-invasively by the SphygmoCor device. This device also measures the central (aortic) BP and simultaneously measures pulse wave velocity (PWV). A bottle of 30 capsules containing either vitamin D or placebo will be given to the subjects and will be asked to take one capsule every day for next month till the second visit. A questionnaire to assess the dietary habits, tobacco use, sun exposure, physical activity, socio-economic status and family health history will be given to the subject. At the dental clinic, full mouth clinical measurements (periodontal probing) will be performed. A plaque sample will be taken and a gum biopsy will be taken to examine the dendritic cells. Also, a saliva sample will be collected. At visit 2: one month later, the supplements will be replenished, compliance will be assessed, and subjects will be examined for any potential side effects. At visit 3: at 8-week follow up, anthropometric measures, blood samples as well as BP and PWV will be measured and the subject will be assessed for clinical improvement in the periodontitis. All the subjects, irrespective of their group assignment will undergo intensive scaling and root planing (S&RP). The supplements will be replenished, compliance will be assessed, and subjects will be examined for any potential side effects. Another fasting blood draw, BP measurement and PWV will be performed approximately 24 hours after the S&RP. Also, the investigators will collect saliva sample during this visit. At visit 4: at 12-week follow up, the procedure in this visit are similar to the visit 2. At visit 5: at 16-week follow up, a post-test evaluation of vitamin D status, cardiovascular phenotypes and periodontitis will be done at the end of the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Periodontal Disease, Vitamin D Deficiency

7. Study Design

Primary Purpose
Prevention
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
cholecalciferol
Arm Type
Active Comparator
Arm Description
Subjects will take 4000 IU per day for 30 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will take placebo everyday for 30 days
Intervention Type
Drug
Intervention Name(s)
Cholecalciferol
Other Intervention Name(s)
Vitamin D3
Intervention Description
subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
sugar pill
Intervention Description
subjects will receive placebo one pill per day for 16 weeks
Primary Outcome Measure Information:
Title
Change in Periodontal Disease Activity
Description
Periodontal disease activity will be measured using standard periodontal disease measures of pocket depth, blood on probing, periodontal inflamed surface area, plaque scores, bone loss, and clinical attachment loss
Time Frame
Baseline, 8 Weeks, 16 weeks.
Title
Change in Cardiometabolic Risk Factors
Description
Cardiometabolic risk factors will be measured by pulse wave velocity, central and peripheral blood pressure and glycated hemoglobin (A1C)
Time Frame
Baseline, 8 Weeks, 24hrs post-Scaling and Root planing, 16 weeks.
Secondary Outcome Measure Information:
Title
Change in Blood Myeloid Dendritic Cells
Description
Relative gene expression (transcripts) in blood myeloid dendritic cells (mDCs) by polymerase chain reaction (PCR) array, validated by protein, of markers of DC homeostasis and atherogenesis.
Time Frame
Baseline, 8 Weeks, 24hrs post-Scaling and Root planing, 16 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: You are African American You have generalized chronic moderate to severe gum disease (periodontitis) Your age is between 18-60 years. You are not taking any vitamin, mineral or herbal supplements If you are a female, you are not pregnant Exclusion Criteria: Not meeting any of the above
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yanbin Dong, PhD
Phone
706-721-5410
Email
ydong@gru.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yanbin Dong, PhD
Organizational Affiliation
Augusta University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Georgia Prevention Institute
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30912
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anas Raed
Phone
706-721-1764
First Name & Middle Initial & Last Name & Degree
Yanbin Dong, MD, PhD

12. IPD Sharing Statement

Learn more about this trial

Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease

We'll reach out to this number within 24 hrs